Emerging Companies Look To Niche Hot Spots For Partnering
You may also be interested in...
Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
With a decision by FDA on a new filing for flibanserin possible by the fall, Sprout hopes to gain the first U.S. approval for treating women with low sexual desire. Meanwhile, Palatin forges on to Phase III with its female sexual desire disorder drug bremelanotide after discussing endpoints with FDA.
Resurrected Flibanserin Filing Tests FDA Position On Female Sexual Desire Disorders
With a decision by FDA on a new filing for flibanserin possible by the fall, Sprout hopes to gain the first U.S. approval for treating women with low sexual desire. Meanwhile, Palatin forges on to Phase III with its female sexual desire disorder drug bremelanotide after discussing endpoints with FDA.
Top Partnering Opportunities In Neuroscience: The Ugly Truth
Consultant notes some promising candidates in a challenging space for investment.